Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kudosil + Culmerciclib + trastuzumab + pertuzumab neoadjuvant therapy in HR+/HER2+ breast cancer
ChiCTR2600121242Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inavolisib, culmerciclib, letrozole, trastuzumab and pertuzumab in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: tpCR (total pathological complete response). Started Mar 2026; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600121242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121242.